COVID-19 UPDATE:

We look forward to welcoming you to the 3rd TPD Summit this October 13-15. You can find our update on COVID-19 here

TPD Summit 2020

Finally Drug the “Undruggable” Through Targeted Protein Degradation

With the first two PROTAC-based therapies reaching the clinical setting last year, the field of targeted protein degradation is undoubtably redefining the therapeutic landscape across the whole of the pharmaceutical industry. Despite the evident success, significant challenges are continuing to hold back the progress of the discovery and development of safe and effective protein degraders.

Returning to Boston in the fall, the 3rd Targeted Protein Degradation (TPD) Summit, as the most comprehensive and definitive event in the field of protein degradation, is proud to showcase the very latest case studies and unique perspectives from 60+ pioneering experts to enable you to successfully degrade intracellular and extracellular targets, leverage the power of the ubiquitin- proteasome system & autophagy-mediated degradation and optimize PK/PD properties of next generation protein degraders for applications in oncology and beyond.

As TPD-based therapeutics continue to generate a new frontier in the field of medicine, join 450+ leaders including C-Level Executives, VPs, & Directors of the leading biopharmaceutical organizations to gain a unique insight into the latest developments of the field and walk away with valuable connections and future directions to drive forward your TPD strategies.

What You Can Expect at TPD Summit 2020:

Event in Numbers

Our Expert Speaker Faculty Includes:

Jay Bradner

President

Novartis Institutes for Biomedical Research

Craig Crews

John C. Malone Professor of MCDB, Chemistry & Pharmacology

Yale University

Alessio Ciulli

Professor of Chemical & Structural Biology

University of Dundee

Matthew Disney

Professor of Chemistry & Neuroscience

Scripps Research

Ray Deshaies

Senior Vice President of Global Research

Amgen

John Houston

President & Chief Executive Officer

Arvinas

Scott Edmondson

Director & Head of Boston Oncology Chemistry

AstraZeneca

Philipp Cromm

Discovery Chemist

Bayer

Ingrid Wertz

Principal Scientist & Project Team Lead

Genentec

Nello Mainolfi

Founder, President & Chief Executive Officer

Kymera Therapeutics

“TPD has expanded from a chemical biology tool to a therapeutic modality that redefines the “druggable” target landscape. This meeting will highlight key findings in the field of protein degradation and demonstrate the journey from degrader to therapeutic”

Jay Bradner, President, Novartis Institutes for Biomedical Research

download

Partners Confirmed For 2020

Life Sensors
Bio-Techne Logo
BioTheryx
MERCK_MSIG_RRed_RGB (1)
Logo
Proteome-Sciences-Plc

Other Events in the Undruggable Series